Drug or intervention
Botulinum toxin type A Clinical Trials
Studies that test Botulinum toxin type A, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 150Spinal Cord Injury, Spasticity
Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury
Spasticity is a common consequence of spinal cord injury and can have a profound impact on quality of life. The goal of this study is to learn if an intervention called focused extracorporeal shockwave therapy can enhance the…
- Trial name
- NCT07894991
- Testing
- Focused extracorporeal shockwave therapy, Botulinum toxin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kessler Foundation
Hernia Abdominal Wall, Botox Injection
Preoperative BOTOX® Injection for Large Ventral Hernia Repair
This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as "BOTOX®" (onabotulinumtoxinA) into the…
- Conditions
- Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome
- Trial name
- PRETOX (NCT07220382)
- Testing
- OnabotulinumtoxinA Injection, OnabotulinumtoxinA, 0.9 % Normal Saline
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- The Cleveland Clinic
Piriformis Muscle Syndrome
Efficacy of Botulinum Toxin Versus Placebo on Pain and Health Related Quality of Life of Patients With Piriformis Muscle Syndrome
Piriformis muscle syndrome (PMS) is characterized by symptoms caused by compression or irritation of the sciatic nerve by the piriformis muscle as it exits the sciatic notch.
- Trial name
- PiriTox (NCT07624045)
- Testing
- Botulinum Toxin - A injections
- Where
- 7 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy
Perineural Botulinum Toxin Injection Versus Oral Duloxetine in Relief of Foot Pain in Painful Peripheral Diabetic Neuropathy
Painful diabetic peripheral neuropathy (DPN) is a frequent and disabling complication of diabetes that commonly causes persistent foot pain, sleep impairment, and decreased quality of life.
- Conditions
- Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Foot Pain, Neuralgia
- Trial name
- NCT07882238
- Testing
- Botulinum Toxin Type A, Duloxetine
- Volunteers
- 56 people
- Sponsor
- Assiut University
Overactive Bladder, Bladder Pain Syndrome
Migraine Medication Effects on Urinary Symptoms
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain.
- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome
- Trial name
- NCT06212661
- Testing
- Ubrogepant, Rimegepant, Atogepant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Cleft Lip, Cleft Lip Scar
Cleft Lip Scarring After Botox
This study is investigating whether botulinum toxin type A (Botox) can improve scar appearance after cleft lip repair surgery. Cleft lip repair is commonly performed during infancy, but visible scarring can occur as the incision…
- Trial name
- CLSAB (NCT07880860)
- Testing
- Botulinum Toxin Type A (BOTOX) Injection, Normal Saline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's National Research Institute
Masticatory Myofascial Pain Syndrome
MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain
The goal of this clinical trial is to learn which magnetic resonance images are best able to assess and predict if a participant with masticatory myofascial pain syndrome will benefit from Botox injections, as compared to placebo…
- Trial name
- NCT07878780
- Testing
- Onabotulinumtoxin A
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Weill Medical College of Cornell University
Magnesium, Botulinum Toxin Type A
Can Adjunctive Oral Magnesium Supplementation Prolong the Effect of Botulinum Toxin Type A in Excessive Gingival Display?
To evaluate and compare the effect of adjuvant oral magnesium supplementation combined with Botulinum Toxin Type A versus Botulinum Toxin Type A alone on the reduction of millimeter gingival display and the duration of clinical…
- Conditions
- Magnesium, Botulinum Toxin Type A, Excessive Gingival Display, Oral
- Trial name
- NCT07874009
- Testing
- Oral Magnesium Glycinate capsules, ● BoNT-A Injection Alone (Day 0)
- Where
- Egypt
- Volunteers
- 26 people
- Sponsor
- Cairo University
Excessive Gingival Display
Decision Regret Following Yonsei-Point Botulinum Toxin for Gummy Smile
This study evaluates patient-reported decision regret in adult patients who previously received standardized Botulinum Toxin Type A (BoNT-A) injection at the Yonsei Point for excessive gingival display (gummy smile).
- Trial name
- NCT07874022
- Testing
- Botulinum Toxin Type A injection at Yonsei Point
- Where
- 2 sites in Egypt
- Volunteers
- 32 people
- Sponsor
- Cairo University
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Completed, with results posted
All 298Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Bruxism, Temporomandibular Disorders (TMD)
Short-Term Symptom Changes in Adults With Teeth Clenching or Grinding and Jaw Symptoms Receiving Splint, Botulinum Toxin, or Medication Plus Splint Care
This prospective observational study evaluated short-term patient-reported symptom changes in adults with bruxism-related and temporomandibular disorder symptoms who received one of three clinically selected management…
- Conditions
- Bruxism, Temporomandibular Disorders (TMD), Myofascial Pain
- Trial name
- NCT07586072
- Testing
- Occlusal splint, Botulinum Toxin Type A (Dysport®), Thiocolchicoside
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Recep Tayyip Erdogan University
Neuropathic Pain
Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain
Onabotulinum toxin type A (BoNT-A) is a potent neurotoxin that has been reported to have an effect on afferent (sensory) neurons independent of its action on muscle tone and secretory glands at the periphery.In human studies, the…
- Trial name
- NCT03848143
- Testing
- onabotulinum toxin A
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Isabel Moreno Hay
Spasmodic Dysphonia
Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
One initial study has shown that Botulinum Toxin (BT) in combination with zinc supplementation may increase the duration of effects BT treatment. This initial study was in the context of facial aesthetics.
- Trial name
- NCT05892770
- Testing
- Zinc gluconate supplement, Botulinum toxin type A
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Florida
Upper Limb Spasticity
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to…
- Trial name
- DIRECTION (NCT04936542)
- Testing
- AboBoNT-A, OnaBoNT-A
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 464 people
- Sponsor
- Ipsen